Brokerages Set Thermo Fisher Scientific Inc. (NYSE:TMO) Target Price at $619.41

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) have earned a consensus recommendation of “Moderate Buy” from the twenty-three analysts that are currently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $619.4091.

A number of research firms have commented on TMO. Sanford C. Bernstein started coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They set a “market perform” rating and a $520.00 target price on the stock. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. HSBC lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their target price for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Barclays lifted their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Finally, Jefferies Financial Group restated a “buy” rating and set a $630.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd.

Key Headlines Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher introduced the Thermo Scientific EMPAD G2 electron detector, designed to enable faster, high-speed four-dimensional scanning transmission electron microscopy. The product could support demand for the company’s analytical-instrument portfolio and strengthen its position in advanced materials research. Thermo Fisher Scientific Introduces the EMPAD G2 Electron Detector
• Positive Sentiment: A recent analysis examines whether Isora could provide Thermo Fisher with an additional long-term growth opportunity, potentially broadening the company’s exposure to emerging research and laboratory markets. Can Isora Unlock a New Growth Edge?
• Neutral Sentiment: Thermo Fisher’s latest reported quarter showed solid momentum: adjusted EPS of $6.03 exceeded estimates, revenue reached $11.99 billion, and sales increased 10.5% year over year. Fiscal 2026 EPS guidance remains $24.93-$25.33, but much of this strength may already be reflected in the stock’s elevated valuation.
• Neutral Sentiment: Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating, although the average price target of $619.41 is below recent trading levels. Several firms have raised targets toward $650, suggesting optimism but limited upside at the current valuation.
• Negative Sentiment: CEO Marc Casper sold 275 shares for approximately $172,000 after selling 10,000 shares worth about $6.3 million earlier in the month. Both transactions were executed under pre-arranged Rule 10b5-1 plans, reducing their significance as a signal of deteriorating fundamentals, but the sales can still weigh on sentiment.

Insider Activity

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 275 shares of Thermo Fisher Scientific stock in a transaction on Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $77,707,171.25. This represents a 0.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 73,768 shares of company stock valued at $44,122,820 over the last 90 days. 0.33% of the stock is currently owned by corporate insiders.

Institutional Trading of Thermo Fisher Scientific

A number of institutional investors have recently made changes to their positions in the business. VELA Investment Management LLC boosted its holdings in Thermo Fisher Scientific by 15.7% in the second quarter. VELA Investment Management LLC now owns 11,167 shares of the medical research company’s stock worth $5,599,000 after acquiring an additional 1,513 shares in the last quarter. HighTower Advisors LLC boosted its stake in Thermo Fisher Scientific by 9.8% in the 2nd quarter. HighTower Advisors LLC now owns 159,181 shares of the medical research company’s stock worth $79,807,000 after purchasing an additional 14,180 shares in the last quarter. Advus Financial Partners LLC purchased a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $250,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Thermo Fisher Scientific during the 2nd quarter valued at approximately $6,969,000. Finally, California State Teachers Retirement System raised its holdings in shares of Thermo Fisher Scientific by 49,331.5% in the second quarter. California State Teachers Retirement System now owns 282,654,735 shares of the medical research company’s stock worth $141,711,778,000 after buying an additional 282,082,924 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $630.66 on Tuesday. The company has a market capitalization of $233.18 billion, a P/E ratio of 33.92, a P/E/G ratio of 2.58 and a beta of 0.85. The company’s 50-day simple moving average is $555.52 and its two-hundred day simple moving average is $511.31. Thermo Fisher Scientific has a one year low of $435.27 and a one year high of $647.00. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the previous year, the firm posted $4.28 earnings per share. The company’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.